RASP (Actavia Life Sciences) Ending Cash Position: $0.00 Mil (As of Mar. 2024)


What is Actavia Life Sciences Ending Cash Position?

Actavia Life Sciences RASP -87.50% Ending Cash Position is $0.00 Mil as of Mar. 2024.

Actavia Life Sciences's Ending Cash Position for the quarter that ended in Mar. 2024 was $0.00 Mil.

Actavia Life Sciences's quarterly Ending Cash Position declined from Sep. 2023 ($0.08 Mil) to Dec. 2023 ($0.02 Mil) and declined from Dec. 2023 ($0.02 Mil) to Mar. 2024 ($0.00 Mil).

Actavia Life Sciences's annual Ending Cash Position increased from Sep. 2021 ($0.01 Mil) to Sep. 2022 ($0.04 Mil) and increased from Sep. 2022 ($0.04 Mil) to Sep. 2023 ($0.08 Mil).

Actavia Life Sciences Ending Cash Position Related Terms

Actavia Life Sciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Ending Cash Position Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.01 0.01 0.04 0.08

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.08 0.02 0.00

Actavia Life Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Actavia Life Sciences's Ending Cash Position for the fiscal year that ended in Sep. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.04+0.035
=0.08

Actavia Life Sciences's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.019+-0.018
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.00 Mil mean?
Actavia Life Sciences (RASP) has a Ending Cash Position of $0.00 Mil as of Mar. 2024. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Ending Cash Position too high?
Actavia Life Sciences' current Ending Cash Position is $0.00 Mil.
How does Actavia Life Sciences' Ending Cash Position compare to BWV and FNCH?
Actavia Life Sciences' Ending Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current Ending Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Ending Cash Position of $0.00 Mil. The current Ending Cash Position is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Ending Cash Position is $0.00 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.